Skip to content
Back to Investors
EI

E Ink

Other

Portfolio

1

companies

By category

  • BioTech£88.4M

By location

  • Cambridge£88.4M

Portfolio companies

Nuclera

Nuclera

Nuclera builds desktop bioprinters to accelerate protein expression and research workflows.


Recent investments

Series C
£57.0M

The Series C financing was led by Elevage Medical Technologies with backing from Patient Square Capital and other investors.

"This significant investment demonstrates continued confidence in our team, our eProtein Discovery system, and our potential to revolutionize the way proteins are made. This funding will accelerate our mission to provide ready-to-use benchtop protein screening and making tools to empower protein scientists around the world. We are excited to enhance our support for our customers, enabling them to make proteins for drug discovery more efficiently and effectively for many years to come."
— Michael Chen, CEO
Series B
£31.4M

The Cambridge biotechnology company has raised £31.4m from investors including M&G and Amadeus Capital Partners to advance its desktop protein printer.

"There’s a fundamental productivity problem in biotech today. A biotech scientist needs to know how to make proteins to design drugs. That’s like expecting a computer scientist to know how to build a computer to design software,"
— Michael Chen, CEO